Related Experiment Videos

Theophylline improves pneumogram abnormalities in infants at risk for sudden infant death syndrome

The Journal of Pediatrics
|December 1, 1983
PubMed

Insights

Theophylline significantly improved cardiorespiratory recordings in infants at risk for Sudden Infant Death Syndrome (SIDS). This treatment normalized pneumograms, reducing apnea and periodic breathing, and preventing SIDS deaths.

Area of Science:

  • Pediatrics
  • Neonatology
  • Sleep Medicine

Background:

  • Infants at increased risk for Sudden Infant Death Syndrome (SIDS) often exhibit abnormal cardiorespiratory patterns.
  • Theophylline is a bronchodilator with potential respiratory stimulant effects.

Purpose of the Study:

  • To evaluate the efficacy of theophylline in improving cardiorespiratory recordings (pneumograms) in infants at high risk for SIDS.
  • To assess the impact of theophylline on apnea, periodic breathing, and overall pneumogram normalization.

Main Methods:

  • Eighty infants with abnormal initial pneumograms, including near-SIDS cases and asymptomatic siblings with SIDS family history, received theophylline.
  • Cardiorespiratory recordings (pneumograms) were obtained before and during theophylline treatment.
  • Apnea density, periodic breathing episodes, and longest apneic periods were analyzed.

Main Results:

  • Theophylline treatment led to significant reductions in apnea density (1.6% to 0.3%), periodic breathing (2.7 to 0.3 episodes/100 min), and longest apneic period (13.5 to 10.1 seconds).
  • Pneumogram findings normalized in 87% of near-SIDS infants and 81.5% of asymptomatic siblings.
  • No SIDS deaths occurred in the study cohort.

Conclusions:

  • Theophylline is effective in normalizing abnormal cardiorespiratory patterns in infants at increased risk for SIDS.
  • The treatment appears to mitigate sleep-disordered breathing and prevent SIDS-related outcomes.
  • Theophylline demonstrates a favorable safety profile in this high-risk infant population.

Related Concept Videos